Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mortality results in GUSTO

F Van de Werf1

  • 1Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium.

Australian and New Zealand Journal of Medicine
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

The GUSTO trial found accelerated tissue plasminogen activator (t-PA) with intravenous heparin reduced 30-day mortality by 14% compared to streptokinase (SK) regimens. This translates to ten lives saved per 1000 patients treated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Dabigatran versus warfarin in patients with mechanical heart valves: reply.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Pre-hospital treatment of STEMI patients. A scientific statement of the Working Group Acute Cardiac Care of the European Society of Cardiology.

Acute cardiac care·2011
Same author

Departures from the protocol during conduct of a clinical trial: a pattern from the data record consistent with a learning curve.

Quality & safety in health care·2010
Same author

[Implementation of reperfusion therapy in ST segment elevation myocardial infarction (STEMI). A policy statement from the Belgian Society of Cardiology and its working group of acute cardiology and interventional cardiology].

Revue medicale de Bruxelles·2010
Same author

[Implementation of reperfusion therapy in ST segment elevation myocardial infarction (STEMI). A policy statement from the Belgian Society of Cardiology and its working group of acute cardiology and interventional cardiology].

Revue medicale de Liege·2010
Same journal

Gastroenterological Society of Australia, Annual Scientific Meeting, May 1980.

Australian and New Zealand journal of medicine·2020
Same journal

'A touch of sugar'--a dangerous euphemism still alive and well.

Australian and New Zealand journal of medicine·2001
Same journal

Silent myocardial ischaemia following methysergide overdose.

Australian and New Zealand journal of medicine·2001
Same journal

Extensive jugular and upper limb thrombosis in a patient with factor V Leiden mutation and non-Hodgkin's lymphoma.

Australian and New Zealand journal of medicine·2001
Same journal

Visual loss as the presenting feature of giant cell arteritis.

Australian and New Zealand journal of medicine·2001
Same journal

Lymphoproliferative disease causing angioedema--an uncommon association.

Australian and New Zealand journal of medicine·2001
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Acute myocardial infarction (AMI) treatment aims to restore coronary blood flow and reduce mortality.
  • Thrombolytic therapy is a cornerstone of AMI management, with various agents and administration methods evaluated.
  • The GUSTO trial investigated the efficacy of different thrombolytic strategies in AMI patients.

Purpose of the Study:

  • To compare the 30-day mortality rates of four treatment arms in the GUSTO trial.
  • To evaluate the effectiveness of accelerated tissue plasminogen activator (t-PA) versus streptokinase (SK) in reducing mortality.
  • To identify patient subgroups benefiting most from accelerated t-PA therapy.

Main Methods:

  • The GUSTO trial randomized 40,000+ patients with AMI into four treatment groups.

Related Experiment Videos

  • Treatment arms included streptokinase (SK) with subcutaneous or intravenous heparin, and accelerated tissue plasminogen activator (t-PA) with intravenous heparin.
  • Mortality data was collected at 30 days post-treatment initiation.

    • Main Results:

    • 30-day mortality rates were: SK/SC Heparin (7.2%), SK/IV Heparin (7.4%), accelerated t-PA/IV Heparin (6.3%), and combined SK/t-PA (7.9%).
    • Accelerated t-PA/IV Heparin demonstrated a 14% relative risk reduction in mortality compared to SK regimens.
    • This equates to an absolute risk reduction of 10 lives saved per 1000 patients treated.
    • Subgroup analysis showed greater benefit with t-PA in patients <75 years, anterior infarcts, and those treated within 4 hours of symptom onset.

    Conclusions:

    • Accelerated tissue plasminogen activator (t-PA) combined with intravenous heparin is superior to streptokinase (SK) regimens in reducing 30-day mortality for acute myocardial infarction.
    • The benefits of t-PA are particularly pronounced in younger patients, those with anterior infarcts, and within the first four hours of symptom onset.
    • These findings support the use of accelerated t-PA as a preferred thrombolytic strategy in specific acute myocardial infarction patient populations.